RxDoctor Payments Data

Kimberly Ovalle

Nurse Practitioner · Bedford, OHNPI 1568753804

Payments from drug & device makers

$717in general payments, 2019–2025

Across 12 payments — averaging $59.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$402
  • Mimedx Group, Inc.$128
  • AstraZeneca$116
  • Smith+Nephew$31
  • AbbVie$21
  • Cashflow Solutions, LLC$18

What the payments were for

  • Food & beverage$717100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Organogenesis Inc.6$402
Mimedx Group, Inc.2$128
AstraZeneca1$116
Smith+Nephew1$31
AbbVie1$21
Cashflow Solutions, LLC1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$717 in reported general payments places this provider in the 80th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$193,628
Medicare patients
311
Services billed
2,709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$19,819
LokelmaSodium Zirconium Cyclosilicate34$11,206
JardianceEmpagliflozin28$10,014
XareltoRivaroxaban28$8,795
TradjentaLinagliptin14$3,672
Lacosamide52$2,630
Mirtazapine83$2,504
Tramadol Hcl174$2,394
Pregabalin91$2,378
Potassium Chloride119$1,777
Fentanyl23$1,729
Lorazepam84$1,684
Pantoprazole Sodium51$1,569
Diclofenac Sodium26$1,332
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate27$1,193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$116$11,20634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Bedford

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →